Guideline-Directed Medical Therapy in Heart Failure: The Need for Speed

References

[1] McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021. Vol. 42(36):3599-726

[2] Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022. Vol. 79(17):e263-e421

[3] Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M. The vulnerable phase after hospitalization for heart failure. Nat Rev Cardiol. 2015. Vol. 12(4):220-9

[4] Greene SJ, Fonarow GC, DeVore AD, Sharma PP, Vaduganathan M, Albert NM, et al.. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019. Vol. 73(19):2365-83

[5] Lewis WR, Peterson ED, Cannon CP, Super DM, LaBresh KA, Quealy K, et al.. An organized approach to improvement in guideline adherence for acute myocardial infarction: results with the Get With The Guidelines quality improvement program. Arch Intern Med. 2008. Vol. 168(16):1813-9

[6] Writing Committee; Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, Davis LL, et al.. 2021 Update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021. Vol. 77(6):772-810

[7] McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014. Vol. 371(11):993-1004

[8] MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet. 1999. Vol. 353(9169):2001-7

[9] CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999. Vol. 353(9146):9-13

[10] Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al.. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001. Vol. 344(22):1651-8

[11] Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999. Vol. 341(10):709-17

[12] Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011. Vol. 364(1):11-21

[13] McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. Vol. 381(21):1995-2008

[14] Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al.. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020. Vol. 383(15):1413-24

[15] Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al.. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet. 2022. Vol. 400(10367):1938-52

[16] Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019. Vol. 380(6):539-48

[17] Patolia H, Khan MS, Fonarow GC, Butler J, Greene SJ. Implementing guideline-directed medical therapy for heart failure: JACC focus seminar 1/3. J Am Coll Cardiol. 2023. Vol. 82(6):529-43

[18] Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, et al.. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011. Vol. 377(9766):658-66

[19] Sokos G, Kido K, Panjrath G, Benton E, Page R 2nd, Patel J, et al.. Multidisciplinary care in heart failure services. J Card Fail. 2023. Vol. 29(6):943-58

[20] Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al.. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021. Vol. 385(16):1451-61